Abstract
The background to the discovery and commercial development of the first Streptococcus salivarius probiotic is documented. A 40-year search of the genus Streptococcus for a harmless natural antagonist of Streptococcus pyogenes had as its operational basis a simple deferred antagonism “fingerprinting” procedure, the application of which results in each tested strain being accorded an inhibitor production (P)-type and inhibitor sensitivity (S)-type profile. Systematic application of this schema has opened a “Pandora’s Box” of novel streptococcal bacteriocin-like inhibitory substances (BLIS). The numerically prominent commensal S. salivarius is proposed to have a pivotal population-modulating role within the oral microbiota of humans. The probiotic strain S. salivarius K12 produces several megaplasmid-encoded BLIS including the lantibiotics salivaricin A and salivaricin B. Strain K12 and other BLIS-producing S. salivarius are currently in use or under development for application to the control of a variety of common maladies and infections of the human oral cavity.
Similar content being viewed by others
References
Burton J, Chilcott C, Tagg J (2005) The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics. Oral Dis 11:29–31
Burton JP, Chilcott CN, Moore CJ, Speiser G, Tagg JR (2006) A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodor parameters. J Appl Microbiol 100:754–764
Burton JP, Wescombe PA, Tagg JR, Chilcott CN (2006) Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl Environ Microbiol 72:3050–3053
Cosseau C, Devine DA, Dullaghan E, Gardy JL, Chikatamarla A, Gellatly S, Yu LL, Pistolic J, Falsafi R, Tagg J, Hancock RE (2008) The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis. Infect Immun 76:4163–4175
Dierksen KP, Tagg JR (2000) The influence of indigenous bacteriocin-producing Streptococcus salivarius on the acquisition of Streptococcus pyogenes by primary school children in Dunedin, New Zealand. In: Martin DR, Tagg JR (eds) Streptococci and streptococcal diseases: entering the new millennium. Securacopy, Auckland, pp 81–85
Dierksen KP, Moore CJ, Inglis M, Wescombe PA, Tagg JR (2007) The effect of ingestion of milk supplemented with salivaricin A-producing Streptococcus salivarius on the bacteriocin-like inhibitory activity of streptococcal populations on the tongue. FEMS Microbiol Ecol 59:584–591
Hale JDF, Balakrishnan M, Tagg JR (2004) Genetic basis for mutacin N and of its relationship to mutacin I. Indian J Med Res 119(Suppl):247–251
Hale JDF, Ting YT, Jack RW, Tagg JR, Heng NCK (2005) Bacteriocin (mutacin) production by Streptococcus mutans UA159: elucidation of the antimicrobial repertoire by genetic dissection. Appl Environ Microbiol 71:7613–7617
Heng NCK, Burtenshaw GA, Jack RW, Tagg JR (2004) Sequence analysis of pDN571, a plasmid encoding novel bacteriocin production in M-type 57 Streptococcus pyogenes. Plasmid 52:225–229
Heng NCK, Ragland NL, Swe PM, Baird HJ, Inglis MA, Tagg JR, Jack RW (2006) Dysgalacticin: a novel, plasmid-encoded antimicrobial protein (bacteriocin) produced by Streptococcus dysgalactiae subsp. equisimilis. Microbiology 152:1991–2001
Heng NCK, Swe PM, Ting Y-T, Dufour M, Baird HJ, Ragland NL, Burtenshaw GA, Jack RW, Tagg JR (2006) The large antimicrobial proteins (bacteriocins) of streptococci. In: XVIth Lancefield international symposium on streptococci and streptococcal diseases, Palm Cove, Australia, 25–29 September 2005. International congress series, vol 1289, pp 351–354
Heng NCK, Burtenshaw GA, Jack RW, Tagg JR (2007) Ubericin A, a class IIa bacteriocin produced by Streptococcus uberis. Appl Environ Microbiol 73:7763–7766
Heng NCK, Tagg JR, Tompkins GR (2007) Competence-dependent bacteriocin production by Streptococcus gordonii DL1 (Challis). J Bacteriol 189:1468–1472
Heng NCK, Wescombe PA, Burton JP, Jack RW, Tagg JR (2007) The diversity of bacteriocins produced by gram-positive bacteria. In: Riley MA, Chavan M (eds) Evolution and ecology of bacteriocins. Springer, New York, pp 45–92
Hyink O, Balakrishnan M, Tagg JR (2005) Streptococcus rattus strain BHT produces both a class I two-component lantibiotic and a class II bacteriocin. FEMS Microbiol Lett 252:235–244
Hyink O, Wescombe PA, Upton M, Ragland N, Burton JP, Tagg JR (2007) Salivaricin A2 and the novel lantibiotic salivaricin B are encoded by adjacent loci on a 190 kb transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol 73:1107–1113
Jack RW, Carne A, Metzger J, Stefanovic S, Sahl H-G, Jung G, Tagg JR (1994) Elucidation of the structure of SA-FF22, a lanthionine-containing antibacterial peptide produced by Streptococcus pyogenes strain FF22. Eur J Biochem 220:455–462
Kazor CE, Mitchell PM, Lee AM, Stokes LN, Loesche WJ, Dewhirst FE, Paster BJ (2003) Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. J Clin Microbiol 41:558–563
Liljemark WF, Gibbons RJ (1973) Suppression of Candida albicans by human oral streptococci in gnotobiotic mice. Infect Immun 8:846–849
Pasteur L, Joubert JF (1877) Charbon et septicemie. C R Soc Biol Paris 85:101–115
Phelps HA, Neely MN (2007) SalY of the Streptococcus pyogenes lantibiotic locus is required for full virulence and intracellular survival in macrophages. Infect Immun 75:4541–4551
Power DA, Burton JP, Chilcott CN, Dawes PJ, Tagg JR (2008) Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis 27:1261–1263
Robson CL, Wescombe PA, Klesse NA, Tagg JR (2007) Isolation and partial characterisation of the Streptococcus mutans type AII lantibiotic mutacin K8. Microbiology 153:1631–1641
Ross KF, Ronson CW, Tagg JR (1993) Isolation and characterization of the lantibiotic salivaricin A and its structural gene salA from Streptococcus salivarius 20P3. Appl Environ Microbiol 59:2014–2021
Simmonds RS, Simpson WJ, Tagg JR (1997) Cloning and sequence analysis of zooA, a Streptococcus zooepidemicus gene encoding a bacteriocin-like inhibitory substance having a domain structure similar to that of lysostaphin. Gene 189:255–261
Simpson WJ, Tagg JR (1983) M-type 57 group A streptococcus bacteriocin. Can J Microbiol 29:1445–1451
Sklavounou A, Germaine GR (1980) Adherence of oral streptococci to keratinized and nonkeratinized human oral epithelial cells. Infect Immun 27:686–689
Swe PM, Heng NC, Ting YT, Baird HJ, Carne A, Tauch A, Tagg JR, Jack RW (2007) ef1097 and ypkK encode enterococcin V583 and corynicin JK, members of a new family of antimicrobial proteins (bacteriocins) with modular structure from Gram-positive bacteria. Microbiology 153:3218–3227
Tagg JR (1991) Studies of “BLIS-ful” oral bacteria. N Z Dent J 87:14–16
Tagg JR (1992) BLIS production in the genus Streptococcus. In: James R, Lazdunski C, Pattus F (eds) Bacteriocins, microcins and lantibiotics. Springer-Verlag, Heidelberg, pp 417–420
Tagg JR (2004) Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Indian J Med Res 119(Suppl):13–16
Tagg JR, Bannister LV (1979) ”Fingerprinting” ß-haemolytic streptococci by their production of and sensitivity to bacteriocine-like inhibitors. J Med Microbiol 12:397–411
Tagg JR, McGiven AR (1972) Some possible autoimmune mechanisms in rheumatic carditis. Lancet 2:686–688
Tagg JR, Mushin R (1971) Epidemiology of Pseudomonas aeruginosa infection in hospitals. 1. Pyocine typing of Ps. aeruginosa. Med J Aust 1:847–852
Tagg JR, Wannamaker LW (1978) Streptococcin A-FF22: nisin-like antibiotic substance produced by a group A streptococcus. Antimicrob Agents Chemother 14:31–39
Tagg JR, Read RSD, McGiven AR (1971) Bacteriocine production by group A streptococci. Pathology 3:277–278
Tagg JR, Dajani AS, Wannamaker LW (1975) Bacteriocin of a group B streptococcus: partial purification and characterization. Antimicrob Agents Chemother 7:764–772
Tagg JR, Dajani AS, Wannamaker LW (1976) Bacteriocins of gram-positive bacteria. Bacteriol Rev 40:722–756
Tompkins GR, Tagg JR (1989) The ecology of bacteriocin-producing strains of Streptococcus salivarius. Microb Ecol Health Dis 2:19–28
Walls T, Power D, Tagg J (2003) Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media? J Med Microbiol 52:829–833
Wescombe PA, Tagg JR (2003) Purification and characterisation of streptin, a type A1 lantibiotic produced by Streptococcus pyogenes. Appl Environ Microbiol 69:2737–2747
Wescombe PA, Heng NCK, Jack RW, Tagg JR (2005) Bacteriocins associated with cytotoxicity for eukaryotic cells. In: Proft T (ed) Microbial toxins, a critical review. Horizon Press, Wymondham, pp 399–448
Wescombe PA, Burton JP, Cadieux PA, Klesse NA, Hyink O, Heng NCK, Chilcott CN, Reid G, Tagg JR (2006) Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivarius. Antonie Van Leeuwenhoek 90:269–280
Wescombe PA, Upton M, Dierksen KP, Ragland NL, Sivabalan S, Wirawan R, Inglis M, Moore CJ, Walker GV, Chilcott C, Jenkinson HF, Tagg JR (2006) Production of the lantibiotic salivaricin A and its variants by oral streptococci and the use of a specific induction assay to detect their presence in human saliva. Appl Environ Microbiol 72:1459–1466
Wirawan RE, Klesse NA, Jack RW, Tagg JR (2006) The production and characterization of a novel nisin variant by Streptococcus uberis. Appl Environ Microbiol 72:1148–1156
Wirawan RE, Swanson KM, Kleffman T, Jack RW, Tagg JR (2007) Uberolysin: a novel cyclic bacteriocin produced by Streptococcus uberis. Microbiology 153:1619–1630
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tagg, J.R. Streptococcal Bacteriocin-Like Inhibitory Substances: Some Personal Insights into the Bacteriocin-Like Activities Produced by Streptococci Good and Bad. Probiotics & Antimicro. Prot. 1, 60–66 (2009). https://doi.org/10.1007/s12602-008-9002-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12602-008-9002-7